Literature DB >> 21593139

Downregulation of Sec23A protein by miRNA-375 in prostate carcinoma.

Jaroslaw Szczyrba1, Elke Nolte, Sven Wach, Elisabeth Kremmer, Robert Stöhr, Arndt Hartmann, Wolf Wieland, Bernd Wullich, Friedrich A Grässer.   

Abstract

Prostate carcinoma (CaP) is a leading cause of cancer-related death in men. We have previously determined the microRNA (miRNA) profile of primary CaP in comparison with nontumor prostate tissue. miRNAs are small, noncoding RNAs that inhibit protein synthesis on a posttranscriptional level by binding to the 3'-untranslated region (3'-UTR) of their target genes. In primary CaP tissue, we have previously found by miRNA sequencing that miR-375 and miR-200c were upregulated 9.1- and 4.5-fold, respectively. A computational analysis predicted the 3'-UTR of the SEC23A gene as a potential target for both miR-375 and miR-200c. Here, we show that the 3'-UTR of SEC23A mRNA is indeed a target for miR-375 and miR-200c and that both miRNAs downregulate Sec23A protein expression when ectopically expressed in human 293T cells. In primary samples of CaP, we found a direct correlation between reduction of SEC23A mRNA and overexpression of miR-375 but not of miR-200c. The reduced levels of Sec23A protein were inversely correlated to the increased amount of miR-375 in the LNCaP and DU145 CaP cell lines when compared with normal prostate fibroblasts. In primary CaP, we also detected decreased amounts of Sec23A protein when compared with corresponding normal prostate tissue. Ectopically overexpressed Sec23A in LNCaP and DU145 CaP cells significantly reduced the growth properties, indicating that Sec23A might play a role in the induction or growth of prostate carcinoma. Sec23A overexpression reduced cell growth but did not induce apoptosis, whereas inhibition of Sec23A stimulated cell proliferation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21593139     DOI: 10.1158/1541-7786.MCR-10-0573

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  45 in total

Review 1.  Prostate cancer: the need for biomarkers and new therapeutic targets.

Authors:  Juliana Felgueiras; Joana Vieira Silva; Margarida Fardilha
Journal:  J Zhejiang Univ Sci B       Date:  2014-01       Impact factor: 3.066

Review 2.  Regulation of cancer metastasis by cell-free miRNAs.

Authors:  Maša Alečković; Yibin Kang
Journal:  Biochim Biophys Acta       Date:  2014-10-28

3.  Targeting MYCN IRES in MYCN-amplified neuroblastoma with miR-375 inhibits tumor growth and sensitizes tumor cells to radiation.

Authors:  Hailong Zhang; Tao Liu; Sha Yi; Lubing Gu; Muxiang Zhou
Journal:  Mol Oncol       Date:  2015-03-24       Impact factor: 6.603

4.  Expression differences of circulating microRNAs in metastatic castration resistant prostate cancer and low-risk, localized prostate cancer.

Authors:  Han Christine Ngoc Nguyen; Wanling Xie; Ming Yang; Chen-Lin Hsieh; Sarah Drouin; Gwo-Shu Mary Lee; Philip W Kantoff
Journal:  Prostate       Date:  2012-08-10       Impact factor: 4.104

5.  MiR-375 targets KLF4 and impacts the proliferation of colorectal carcinoma.

Authors:  Qiqi Mao; Tao Quan; Bin Luo; Xuefeng Guo; Lei Liu; Qinghui Zheng
Journal:  Tumour Biol       Date:  2015-07-30

Review 6.  miRNAs as biomarkers in prostate cancer.

Authors:  Irene Casanova-Salas; José Rubio-Briones; Antonio Fernández-Serra; Jose Antonio López-Guerrero
Journal:  Clin Transl Oncol       Date:  2012-07-24       Impact factor: 3.405

7.  Binding of the heterogeneous ribonucleoprotein K (hnRNP K) to the Epstein-Barr virus nuclear antigen 2 (EBNA2) enhances viral LMP2A expression.

Authors:  Henrik Gross; Christine Hennard; Ilias Masouris; Christian Cassel; Stephanie Barth; Ute Stober-Grässer; Alfredo Mamiani; Bodo Moritz; Dirk Ostareck; Antje Ostareck-Lederer; Nils Neuenkirchen; Utz Fischer; Wen Deng; Heinrich Leonhardt; Elfriede Noessner; Elisabeth Kremmer; Friedrich A Grässer
Journal:  PLoS One       Date:  2012-08-03       Impact factor: 3.240

8.  Cell-free Circulating miRNA Biomarkers in Cancer.

Authors:  Meng-Hsuan Mo; Liang Chen; Yebo Fu; Wendy Wang; Sidney W Fu
Journal:  J Cancer       Date:  2012-10-13       Impact factor: 4.207

Review 9.  Circulating microRNAs as potential new biomarkers for prostate cancer.

Authors:  A Sita-Lumsden; D A Dart; J Waxman; C L Bevan
Journal:  Br J Cancer       Date:  2013-04-30       Impact factor: 7.640

10.  MicroRNA-142 is mutated in about 20% of diffuse large B-cell lymphoma.

Authors:  Wiyada Kwanhian; Dido Lenze; Julia Alles; Natalie Motsch; Stephanie Barth; Celina Döll; Jochen Imig; Michael Hummel; Marianne Tinguely; Pankaj Trivedi; Viraphong Lulitanond; Gunter Meister; Christoph Renner; Friedrich A Grässer
Journal:  Cancer Med       Date:  2012-09-18       Impact factor: 4.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.